Sophie L. Gerritse YOU? Author Swipe

Last 10y

Supplementary Figure S1 from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sarah R. Verhoeff, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse, Lindsay Angus , et al. · 2025

Flow diagram of patient enrolment. * Four patients were unfit for systemic treatment due to clinical deterioration resulting from rapid disease progression (n=3) or comorbidity and age (n=1). Three other patients did not wat systemic treat…

Supplement LASSO from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sjoukje F. Oosting, Sjoerd G. Elias, Sophie L. Gerritse, Sandra Heskamp, Ingrid M.E. Desar , et al. · 2025

Lasso model

SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma Open

Jorien B.E. Janssen, Kirti K. Iyer, Sophie L. Gerritse, Eline Janssen, Elske C. Gootjes , et al. · 2025

Background Patients with metastatic colorectal cancer often have poor or short responses to currently available therapies. Drug repurposing with alternative dosing schedules may offer unexpected clinical benefit, even for agents that previ…

Data from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse , et al. · 2023

Purpose:Watchful waiting (WW) can be considered for patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis, especially those with 18F]FDG PET/CT and [⁸⁹Zr]Zr-DFO-girentuximab …

Supplementary Figure S2 from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse , et al. · 2023

Score chart with predicted probability (%) to remain on WW at 12 months This model was based on the number of IMDC Risk factors (0, 1, 2), the number or involved organ sites (0 - 4) and the geometric mean [¹⁸F]FDG SUVmax as a continuous va…

Supplementary Figure S1 from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse , et al. · 2023

Flow diagram of patient enrolment. * Four patients were unfit for systemic treatment due to clinical deterioration resulting from rapid disease progression (n=3) or comorbidity and age (n=1). Three other patients did not wat systemic treat…

Supplementary Figure S1 from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse , et al. · 2023

Flow diagram of patient enrolment. * Four patients were unfit for systemic treatment due to clinical deterioration resulting from rapid disease progression (n=3) or comorbidity and age (n=1). Three other patients did not wat systemic treat…

Supplement LASSO from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse , et al. · 2023

Lasso model

Supplement LASSO from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse , et al. · 2023

Lasso model

Supplementary Figure S3 from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse , et al. · 2023

Flow-chart patients according to RECIST-defined PD. *All patients had clinical disease progression; no CT-imaging was performed before initiation of systemic treatment ** In total 7 patients choose best supportive care. Three other patient…

Supplementary Figure S2 from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse , et al. · 2023

Score chart with predicted probability (%) to remain on WW at 12 months This model was based on the number of IMDC Risk factors (0, 1, 2), the number or involved organ sites (0 - 4) and the geometric mean [¹⁸F]FDG SUVmax as a continuous va…

Supplementary Figure S3 from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse , et al. · 2023

Flow-chart patients according to RECIST-defined PD. *All patients had clinical disease progression; no CT-imaging was performed before initiation of systemic treatment ** In total 7 patients choose best supportive care. Three other patient…

Data from [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse , et al. · 2023

Purpose:Watchful waiting (WW) can be considered for patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis, especially those with 18F]FDG PET/CT and [⁸⁹Zr]Zr-DFO-girentuximab …

High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors Open

Sophie L. Gerritse, Mariëtte Labots, Rob ter Heine, Henk Dekker, Dennis Poel , et al. · 2022

Patients with advanced cancer refractory to standard treatment were treated with sunitinib at a dose of 300 mg once every week (Q1W) or 700 mg once every two weeks (Q2W). Tumor, skin and plasma concentrations were measured and immunohistoc…

[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Open

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse , et al. · 2022

Purpose: Watchful waiting (WW) can be considered for patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis, especially those with <2 International Metastatic RCC Database Consortium criter…

High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review Open

Sophie L. Gerritse, Jorien B.E. Janssen, Mariëtte Labots, Ralph de Vries, Michelle A. Rudek , et al. · 2021

Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen Open

Sophie L. Gerritse, Rob ter Heine, Mariëtte Labots, E. van den Hombergh, Henk Dekker , et al. · 2020

Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer Open

Erik J. van Helden, Sjoerd G. Elias, Sophie L. Gerritse, Suzanne C. van Es, Elles M. J. Boon , et al. · 2020

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer Open

Erik J. van Helden, Sjoerd G. Elias, Sophie L. Gerritse, Suzanne C. van Es, Eline Boon , et al. · 2019

Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results Open

Suzanne C. van Es, Bert van der Vegt, Frederike Bensch, Sophie L. Gerritse, Erik J. van Helden , et al. · 2019

In metastatic breast cancer (MBC), expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) guides treatment selection. In case of bone-only metastatic disease, ER, PR, and HER2 …

Decalcification of Breast Cancer Bone Metastases with EDTA Does Not Affect ER, PR, and HER2 Results Open

Svetukhina Es, B. van deVegt, Frederike Bensch, Sophie L. Gerritse, Erik J. van Helden , et al. · 2019

textabstractIn metastatic breast cancer (MBC), expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) guides treatment selection. In case of bone-only metastatic disease, ER,…

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors Open

Maria Rovithi, Sophie L. Gerritse, Richard J. Honeywell, Albert J. ten Tije, Rita Ruijter , et al. · 2018

PURPOSE Dose and schedule optimization of treatment with tyrosine kinase inhibitors is of utmost importance. On the basis of preclinical data, a phase I clinical trial of once weekly or once every 2 weeks administration of high-dose suniti…

The ‘morning dip’ in antimicrobial appropriateness: circumstances determining appropriateness of antimicrobial prescribing Open

Jonne J. Sikkens, Sophie L. Gerritse, Edgar J.G. Peters, Mark H.H. Kramer, Michiel A. van Agtmael · 2018

Antimicrobial prescribing was less appropriate in the mornings and when prescribed by inexperienced physicians. Appropriateness may be increased by improving prescribing circumstances.

Trends in incidence, treatment and survival of small bowel adenocarcinomas between 1999 and 2013: a population-based study in The Netherlands Open

Laura M. Legué, Nienke Bernards, Sophie L. Gerritse, Thijs R. van Oudheusden, Ignace H. J. T. de Hingh , et al. · 2016

Small bowel adenocarcinomas are rare tumors with an increasing incidence. The administration of adjuvant and palliative chemotherapy doubled, but median overall survival only increased for patients with locoregional disease. Given the rari…

The “Morning Dip” in Antimicrobial Appropriateness Open

Jonne J. Sikkens, Sophie L. Gerritse, Edgar J.G. Peters, Mark S. Kramer, Michiel A. van Agtmael · 2016

A diagnosis based on the electrocardiogram before laboratory results were available Open

Sophie L. Gerritse, E.H.C.C. Janssen · 2015

A diagnosis based on the electrocardiogram before laboratory results were available Open

Sophie L. Gerritse, E.H.C.C. Janssen · 2015

tration.With normalisation of his potassium level, the ECG proved to be normal.His hyperkalaemia was thought to be secondary to (pre-renal) kidney failure by dehydration and the use of perindopril.

Fetching topic information...